Gene Oracle Unleashes GeneIOS

Mountain View, CA, September 23, 2008 --(PR.com)-- Gene Oracle, Inc., a leading provider of molecular reagents and services for synthetic biology, announces the launch of the GeneIOS system, a complete solution for creating synthetic genes in a single day. The Company has created a first of its kind software suite and reagents package that enables researchers in any lab to design and make genes up to 1kb in size, quickly and with high fidelity. GeneIOS provides a cost-effective alternative to expensive gene synthesis service companies and makes the process as quick and easy as PCR.

Making synthetic genes de novo from DNA sequence information provides researchers unprecedented design freedom. In comparison, existing gene construction methods typically requires input DNA from a natural source (i.e. chromosomal DNA); this severely constrains the starting point for design and also requires the subsequent modification of the DNA sequence to make the gene useful in research investigations. Typically, a synthetic gene encodes for the complete amino acid sequence of a protein and is made by assembling overlapping oligonucleotides to yield the desired full length sequence. However, the lack of robust algorithms and software, and the complexity of protocols to convert reagents into the final DNA sequence have severely limited the use of synthetic genes such that researchers typically defer to expensive service-based companies for this product.

The GeneIOS (GeneInformationOperatingSystem) solution includes a software application that incorporates expertise in three critical design parameters: the upfront analysis of the input sequence, the performance optimization of the gene and the creation of a set of optimal oligonucleotide reagents for successful one-step gene synthesis. Gene Oracle then provides a complete reagent package, including high quality oligonucleotides and enzymes, that enables the researcher to assemble a complete synthetic gene in a single reaction and then clone it directly into their preferred vector.

Commenting on the launch Dr. Tony Cox, Ph.D., President and co-founder of Gene Oracle, Inc. said, “GeneIOS represents a complete solution for gene synthesis and puts the process control where it should be: with the individual researcher. The software and reagent package provides the capability for gene synthesis in a day and will dramatically accelerate the uptake of synthetic biology in research settings.”

Until now gene synthesis has been an expensive and time consuming process, provided by a small number of service-based companies. GeneIOS includes expert design and optimization software to allow any user to create synthetic gene constructs at substantially reduced pricing and in a fraction of the time. The GeneIOS software can be downloaded from the company’s website (www.geneoracle.com) as a complementary 30 day trial version or as a licensed professional version.

Founded in 2004, Gene Oracle Inc. is a privately held Mountain View California-based corporation focused on developing and commercializing innovative products and services for the life science research market. Gene Oracle manufactures custom synthetic genes, and provides molecular biology consulting services to pharmaceutical, biotechnology, and academic research institutions. More information about GeneIOS is available at the Company’s website at www.geneoracle.com.

Gene Oracle and GeneIOS are trademarks of Gene Oracle, Inc. all rights reserved.

###